<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
    /* References section styling */
    .refs-section { border: 1px solid var(--border); border-radius: 12px; padding: 16px; background: var(--card); }
    .refs-title { font-size: 16px; font-weight: 700; color: #1f2937; margin: 0 0 16px 0; padding-bottom: 8px; border-bottom: 2px solid var(--accent); }
    .ref-category { margin-bottom: 16px; }
    .ref-cat-header { font-size: 14px; font-weight: 600; color: #374151; margin-bottom: 10px; padding: 6px 10px; background: linear-gradient(135deg, #f3f4f6 0%, #e5e7eb 100%); border-radius: 6px; }
    .ref-entry { margin-bottom: 10px; padding: 10px 12px; background: #fafafa; border-radius: 8px; border-left: 3px solid var(--accent); }
    .ref-tag { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, monospace; font-size: 12px; font-weight: 600; color: var(--accent); margin-bottom: 6px; word-break: break-all; }
    .ref-details { font-size: 13px; color: #4b5563; line-height: 1.6; }
    .ref-detail-line { margin-bottom: 2px; }
    /* Category-specific colors */
    .ref-guidelines .ref-entry { border-left-color: #059669; }
    .ref-guidelines .ref-tag { color: #059669; }
    .ref-literature .ref-entry { border-left-color: #7c3aed; }
    .ref-literature .ref-tag { color: #7c3aed; }
    .ref-clinical-trials .ref-entry { border-left-color: #dc2626; }
    .ref-clinical-trials .ref-tag { color: #dc2626; }
    .ref-clinical-reports .ref-entry { border-left-color: #d97706; }
    .ref-clinical-reports .ref-tag { color: #d97706; }
    /* Mermaid chart styling */
    .mermaid-container { border-color: #10b981; }
    .mermaid-container > summary { color: #059669; }
    .mermaid-chart { padding: 16px; background: linear-gradient(135deg, #f0fdf4 0%, #ecfdf5 100%); border-radius: 10px; margin-top: 10px; overflow-x: auto; }
    .mermaid-chart svg { max-width: 100%; height: auto; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class='card stats-card' style='background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%); border: 2px solid #0ea5e9; margin-bottom: 16px;'>
<h2 style='margin-top: 0; color: #0369a1;'>ğŸ“Š Pipeline Execution Statistics</h2>
<div style='margin-bottom: 12px;'>
<strong>â±ï¸ Total Execution Time:</strong> 156.6 seconds (2åˆ†36ç§’)
</div>
<div style='margin-bottom: 12px;'>
<strong>ğŸ”¢ Total Tokens:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li>Input: 94,579</li>
<li>Output: 2,388</li>
<li>Total: 96,967</li>
</ul>
</div>
<div style='margin-bottom: 8px;'>
<strong>ğŸ¤– Models Used:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li style='margin-bottom: 6px;'>
<strong>meta-llama/llama-3.1-405b-instruct (Openrouter)</strong>: 
23 calls, 
96,967 tokens 
(94,579 in / 2,388 out)
</li>
</ul>
</div>
</div>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-21_08-29-31</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
Recurrent ovarian clear cell carcinoma with metastatic disease requires urgent assessment and treatment planning, but lacks critical molecular information, including BRCA/HRD testing status, HER2, MSI, PDL1, and TMB results.

Core Treatment Strategy:
- Evaluate patient by a gynaecological oncology centre for potential cytoreduction options, given first relapse &gt;6 months after last platinum administration [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].
- Utilize comprehensive NGS panel results, including ATM NM_000051:exon8:c.A947G:p.Y316C mutation, to inform treatment decisions [@OH2203828 | Genomics].
- Obtain missing critical information, including BRCA/HRD testing status, HER2, MSI, PDL1, TMB results, and latest PET-CT report to accurately assess metabolic activity and inform comprehensive treatment decisions.
- Schedule updated PET-CT to assess metabolic activity and adjust treatment strategy as needed.

Change Triggers:
- If PET-CT scan shows increasing metabolic activity, consider intensifying treatment strategy and reassessing patient by a gynaecological oncology centre.
- If critical molecular information becomes available, reassess and adjust treatment strategy based on new information, considering patient&#x27;s ATM NM_000051:exon8:c.A947G:p.Y316C mutation and platinum-resistant disease status.</pre>
<div class='refs-section mt'>
<h3 class='refs-title'>References</h3>
<div class='ref-category ref-guidelines'>
<div class='ref-cat-header'>ğŸ“‹ Guidelines</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: esmo_cpg_epithelialovarian_2023__v00000000, Page 11</div>
<div class='ref-detail-line'>Content: cytoreduction</div>
<div class='ref-detail-line'>o Residual ChT toxicity</div>
<div class='ref-detail-line'>o The patientâ€™s...</div>
</div>
</div>
</div>
<div class='ref-category ref-literature'>
<div class='ref-cat-header'>ğŸ“š Literature</div>
</div>
<div class='ref-category ref-clinical-trials'>
<div class='ref-cat-header'>ğŸ”¬ Clinical Trials</div>
</div>
<div class='ref-category ref-clinical-reports'>
<div class='ref-cat-header'>ğŸ“„ Clinical Reports</div>
<div class='ref-entry'>
<div class='ref-tag'>[@OH2203828 | Genomics]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Genomics ID: OH2203828 | Date: 2022-04-18</div>
<div class='ref-detail-line'>Content: ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1...</div>
</div>
</div>
</div>
</div>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>åµå·¢æ¶æ€§è‚¿ç˜¤ï¼šåµå·¢ç™Œå¤å‘ï¼šæœ¯å‰CA125 45.7 CA199 161 HE4 562022.03.28åœ¨å…¨éº»ä¸‹è¡Œâ€œç˜¤ä½“å‡ç­æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+é˜´é“éƒ¨åˆ†åˆ‡é™¤æœ¯+è…¹è†œåç—…æŸåˆ‡é™¤æœ¯+å¤æ‚è‚ ç²˜è¿æ¾è§£æœ¯+å·¦è¾“å°¿ç®¡æ”¯æ¶ç½®ç®¡æœ¯+è†€èƒ±ä¿®è¡¥æœ¯ã€‚ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œï¼Œç»“åˆT2022-04771é¦–å…ˆè€ƒè™‘ä¸ºé€æ˜ç»†èƒç™Œï¼Œæ­£åœ¨åŠ åšå…ç–«ç»„åŒ–è¿›ä¸€æ­¥æ˜ç¡®ã€‚è‚¿å—å¤§å°çº¦7*4*2.5cmã€‚åŒä¾§åˆ‡ç¼˜é˜´æ€§ï¼Œè‚ å‘¨æ·‹å·´ç»“ï¼ˆ4/15ï¼‰è§ç™Œè½¬ç§»ï¼Œä¼´ç™Œç»“èŠ‚1æšã€‚ï¼ˆè†€èƒ±åå£è‚¿ç˜¤ï¼‰çº¤ç»´è„‚è‚ªç»„ç»‡ï¼Œå±€ç¶çº¤ç»´ç»„ç»‡å¢ç”Ÿã€å«é“è¡€é»„ç´ æ²‰ç§¯ã€æ³¡æ²«æ ·ç»„ç»‡ååº”ï¼Œæœªè§ç™Œç´¯åŠã€‚è¡¥å……è¯Šæ–­1ï¼šã€è¡¥å……æŠ¥å‘Šã€‘ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰å¯ç¬¦åˆåµå·¢é€æ˜ç»†èƒç™Œç´¯åŠã€‚å…ç–«ç»„åŒ–ï¼ˆHI22-06789ï¼‰ç˜¤ç»†èƒï¼šMLH1(ES05)ï¼ˆ+ï¼‰ï¼ŒMSH6ï¼ˆ+ï¼‰ï¼ŒMSH2ï¼ˆ+ï¼‰ï¼ŒPMS2ï¼ˆ+ï¼‰ï¼ŒERï¼ˆéƒ¨åˆ†+ï¼‰ï¼ŒPRï¼ˆå°‘å¼±+ï¼‰ï¼ŒP53ï¼ˆ+/-ï¼‰ï¼ŒWT1ï¼ˆ-ï¼‰ï¼ŒKi-67ï¼ˆ60%+ï¼‰ï¼ŒHNF1Bï¼ˆ+ï¼‰ï¼ŒNapsinAï¼ˆç¶+ï¼‰ï¼ŒP16ï¼ˆ+ï¼‰ï¼ŒPAX8ï¼ˆ+ï¼‰ï¼ŒSALL4ï¼ˆ-ï¼‰ï¼ŒZBTB16ï¼ˆ-ï¼‰æœ¯åç™½ç´«+å¡é“‚åŒ–ç–—6ç¨‹ï¼Œæœ«æ¬¡ï¼š2022.8.172022.08.15ï¼šCA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/mlâ†‘,CEA:1.92ng/ml,HE4:87.90pmol/Lâ†‘,ROMA:23.55%(ç»ç»å‰)â†‘,ROMA.:18.89%(ç»ç»å)MRï¼ˆ2022.07.17ï¼‰ï¼š2022.08.15ï¼šCA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/mlâ†‘,CEA:1.92ng/ml,HE4:87.90pmol/Lâ†‘,ROMA:23.55%(ç»ç»å‰)â†‘,ROMA.:18.89%(ç»ç»å)è‚¿ç˜¤æ ‡å¿—ç‰©ï¼ˆ2022.10.12ï¼‰ï¼šCA19-9:77.20U/mlâ†‘,CA125:89.60U/mlâ†‘,AFP:&lt;0.91ng/ml,CEA:1.31ng/ml,HE4:59.70pmol/L,ROMA:12.07%(ç»ç»å‰)â†‘,ROMA.:36.67%(ç»ç»å)â†‘ã€‚CTï¼ˆ2022.10.25ï¼‰ï¼šè‚å†…å¤šå‘ç»“èŠ‚ï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ï¼Œè½¬ç§»å¯èƒ½ï¼Œè¯·ç»“åˆMRæ£€æŸ¥ã€‚å¦è§è‚å›Šè‚¿åŒå‰ã€‚MRï¼ˆ2022.10.24ï¼‰ï¼šç›†è…”æœ¯åï¼Œéª¶å‰å ä½ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»éª¶éª¨å—ç´¯å¯èƒ½ã€‚ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚2022.11.10å¤–é™¢è¡€å¸¸è§„ï¼šç™½ç»†èƒ 2.36ï¼Œçº¢ç»†èƒ 3.56ï¼Œè¡€çº¢è›‹ç™½ 97ï¼Œè¡€å°æ¿ 153å¤–é™¢ç”ŸåŒ–ï¼šALPã€€105ï¼ŒNA 136ï¼ŒPAB 1242022.11.30å¤–é™¢è¡€å¸¸è§„ï¼šç™½ç»†èƒ 3.46ï¼Œçº¢ç»†èƒ 3.48ï¼Œè¡€çº¢è›‹ç™½ 94ï¼Œè¡€å°æ¿ 1342022.11.17å¤–é™¢è‚¿ç˜¤æŒ‡æ ‡ï¼šCA125ã€€403ï¼ŒCa153ã€€63.8ï¼ŒCa199 96.8ï¼ŒCa724 695è‚¿ç˜¤æ ‡å¿—ç‰©ï¼ˆ2022.12.29ï¼‰ï¼šCA19-9:229.00U/mlâ†‘,CA125:933.00U/mlâ†‘,CA15-3:86.00U/mlâ†‘,CEA:1.49ng/ml,NSE:9.06ng/ml,HE4:111.00pmol/Lâ†‘,ROMA:41.02%(ç»ç»å‰)â†‘,ROMA.:85.98%(ç»ç»å)â†‘ã€‚MRï¼ˆ2022.12.30ï¼‰ï¼šç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚CTï¼ˆ2022.12.30ï¼‰ï¼šè‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚å¦è§è‚å›Šè‚¿åŒå‰ã€‚è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚å’¨è¯¢æŠ¥å‘Š</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;ç™½ç´«+å¡é“‚&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;&lt;0.91 ng/ml (2022-10-12)&quot;,&quot;CA125&quot;:&quot;933.00 U/ml (2022-12-29)&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;High-grade adenocarcinoma involving full-thickness intestinal wall&quot;,&quot;Lymph node metastasis (4/15)&quot;,&quot;Peritoneal/rectal/vaginal involvement described&quot;],&quot;histology&quot;:&quot;é€æ˜ç»†èƒç™Œ; è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œ&quot;,&quot;laterality&quot;:&quot;Unknown&quot;,&quot;primary&quot;:&quot;åµå·¢ç™Œå¤å‘&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Unknown&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;6&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;intent&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;ç™½ç´«+å¡é“‚&quot;,&quot;start_date&quot;:&quot;Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;56&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;56&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;evidence&quot;:&quot;Rise in CA125/CA19-9 on 2022-10-12&quot;,&quot;evidence_type&quot;:&quot;Biochemical&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;Unknown&quot;,&quot;status&quot;:&quot;Resistant&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;56&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Resistant&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Resistant&quot;,&quot;RELAPSE&quot;:&quot;Yes&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;evidence&quot;:&quot;Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence&quot;,&quot;type&quot;:&quot;Biochemical&quot;},&quot;SCENE&quot;:&quot;Platinum_resistant_relapse&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Surgical resection&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚ chemotherapy, last given 2022-08-17&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Post-chemo tumor markers reduced on 2022-08-15&quot;,&quot;regimen_or_test&quot;:&quot;ç™½ç´«+å¡é“‚&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Rising tumor markers indicating recurrence&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9 77.20 U/ml; CA125 89.60 U/ml&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Presacral lesion and pelvic mesenteric nodules, possible metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT shows multiple liver nodules, some new compared to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple hepatic metastatic nodules&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Markedly elevated tumor markers consistent with progression&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Progression of pelvic and hepatic metastatic disease&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis; CT abdomen&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-03&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-08-17&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;14.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;89.60&quot;},{&quot;date&quot;:&quot;2022-11-17&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;403&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;933.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;933.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.16&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;77.20&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;229.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;229.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;87.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;59.70&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;111.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;â†‘&quot;,&quot;value&quot;:&quot;111.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Primary cytoreductive surgery performed&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Biochemical relapse with rising tumor markers&quot;,&quot;type&quot;:&quot;Relapse&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;6 cycles of ç™½ç´«+å¡é“‚, last 2022-08-17&quot;,&quot;last_admin_date&quot;:&quot;2022-08-17&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;ç™½ç´«+å¡é“‚&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;Tumor size ~7x4x2.5 cm&quot;,&quot;Bilateral margins negative&quot;,&quot;Pericolic lymph nodes 4/15 positive&quot;,&quot;One tumor nodule (posterior bladder)&quot;],&quot;date&quot;:&quot;2022-03-28&quot;,&quot;diagnosis&quot;:&quot;Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma&quot;,&quot;grade&quot;:&quot;High-grade&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;MLH1&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;MSH6&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;MSH2&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;PMS2&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;partial+&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;few weak+&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;+/-&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;60%+&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;focal+&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;SALL4&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;ZBTB16&quot;,&quot;result&quot;:&quot;-&quot;}],&quot;involvement_sites&quot;:[&quot;Rectosigmoid colon&quot;,&quot;Left retroperitoneum&quot;,&quot;Vagina&quot;,&quot;Pericolic lymph nodes&quot;,&quot;Posterior bladder nodule&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;åµå·¢æ¶æ€§è‚¿ç˜¤ï¼šåµå·¢ç™Œå¤å‘ï¼šæœ¯å‰CA125 45.7 CA199 161 HE4 562 2022.03.28åœ¨å…¨éº»ä¸‹è¡Œâ€œç˜¤ä½“å‡ç­æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+é˜´é“éƒ¨åˆ†åˆ‡é™¤æœ¯+è…¹è†œåç—…æŸåˆ‡é™¤æœ¯+å¤æ‚è‚ ç²˜è¿æ¾è§£æœ¯+å·¦è¾“å°¿ç®¡æ”¯æ¶ç½®ç®¡æœ¯+è†€èƒ±ä¿®è¡¥æœ¯ã€‚ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œï¼Œç»“åˆT2022-04771é¦–å…ˆè€ƒè™‘ä¸ºé€æ˜ç»†èƒç™Œï¼Œæ­£åœ¨åŠ åšå…ç–«ç»„åŒ–è¿›ä¸€æ­¥æ˜ç¡®ã€‚è‚¿å—å¤§å°çº¦7*4*2.5cmã€‚åŒä¾§åˆ‡ç¼˜é˜´æ€§ï¼Œè‚ å‘¨æ·‹å·´ç»“ï¼ˆ4/15ï¼‰è§ç™Œè½¬ç§»ï¼Œä¼´ç™Œç»“èŠ‚1æšã€‚ï¼ˆè†€èƒ±åå£è‚¿ç˜¤ï¼‰çº¤ç»´è„‚è‚ªç»„ç»‡ï¼Œå±€ç¶çº¤ç»´ç»„ç»‡å¢ç”Ÿã€å«é“è¡€é»„ç´ æ²‰ç§¯ã€æ³¡æ²«æ ·ç»„ç»‡ååº”ï¼Œæœªè§ç™Œç´¯åŠã€‚è¡¥å……è¯Šæ–­1ï¼šã€è¡¥å……æŠ¥å‘Šã€‘ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ +å·¦ä¾§è…¹è†œåè‚¿ç˜¤+éƒ¨åˆ†é˜´é“ï¼‰å¯ç¬¦åˆåµå·¢é€æ˜ç»†èƒç™Œç´¯åŠã€‚å…ç–«ç»„åŒ–ï¼ˆHI22-06789ï¼‰ç˜¤ç»†èƒï¼šMLH1(ES05)ï¼ˆ+ï¼‰ï¼ŒMSH6ï¼ˆ+ï¼‰ï¼ŒMSH2ï¼ˆ+ï¼‰ï¼ŒPMS2ï¼ˆ+ï¼‰ï¼ŒERï¼ˆéƒ¨åˆ†+ï¼‰ï¼ŒPRï¼ˆå°‘å¼±+ï¼‰ï¼ŒP53ï¼ˆ+/-ï¼‰ï¼ŒWT1ï¼ˆ-ï¼‰ï¼ŒKi-67ï¼ˆ60%+ï¼‰ï¼ŒHNF1Bï¼ˆ+ï¼‰ï¼ŒNapsinAï¼ˆç¶+ï¼‰ï¼ŒP16ï¼ˆ+ï¼‰ï¼ŒPAX8ï¼ˆ+ï¼‰ï¼ŒSALL4ï¼ˆ-ï¼‰ï¼ŒZBTB16ï¼ˆ-ï¼‰&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;Partial rectosigmoid + left retroperitoneal tumor + partial vagina&quot;,&quot;tumor_size&quot;:&quot;7 x 4 x 2.5 cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;BRCA/HRD testing not reported&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2022-10-24&quot;,&quot;findings&quot;:[&quot;Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules&quot;],&quot;impression&quot;:&quot;Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Multiple intrahepatic nodules, some new compared to prior&quot;],&quot;impression&quot;:&quot;Probable metastases in liver&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Pelvis; sacrum; right iliac bone&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar&quot;],&quot;impression&quot;:&quot;Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver; spleen&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct&quot;],&quot;impression&quot;:&quot;Progression of hepatic metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Surgical resection&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of ç™½ç´«+å¡é“‚ chemotherapy, last given 2022-08-17&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Post-chemo tumor markers reduced on 2022-08-15&quot;,&quot;regimen_or_test&quot;:&quot;ç™½ç´«+å¡é“‚&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Rising tumor markers indicating recurrence&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA19-9 77.20 U/ml; CA125 89.60 U/ml&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Presacral lesion and pelvic mesenteric nodules, possible metastases&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT shows multiple liver nodules, some new compared to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple hepatic metastatic nodules&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;description&quot;:&quot;Markedly elevated tumor markers consistent with progression&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Progression of pelvic and hepatic metastatic disease&quot;,&quot;regimen_or_test&quot;:&quot;MRI pelvis; CT abdomen&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Clinical Trial Recommendation</summary>
    <pre>None</pre>
    <div class="hint">Shown only when the trial matcher produced a recommendation.</div>
  </details>

  <details class="mt" open>
    <summary>Expert Debate (Round Ã— Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Consider evaluating patient by a gynaecological oncology centre for potential cytoreduction options, given first relapse &gt;6 months after last platinum administration [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Considering patient&#x27;s elevated CA125 and imaging evidence of metastatic disease, further assessment and treatment planning are urgently required [@20221229|9703212 | LAB]. Comprehensive NGS panel results should also inform treatment decisions [@OH2203828 | Genomics].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>chair</td><td>Critical information is missing, including the tumor&#x27;s BRCA/HRD testing status and HER2, MSI, PDL1, and TMB results, as only one molecular report is available [@OH2203828 | Genomics].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>chair</td><td>PET findings are not available; needs update with latest PET-CT report to accurately assess metabolic activity.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;Initial assessment:\n\n* Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging [@2022-12-29 | MR], [@2022-12-29 | CT].\n* Platinum-resistant disease, last platinum treatment ended 2022-08-17, and CA125 933.00 U/ml on 2022-12-29 [@20221229|9703212 | LAB].\n* Consider evaluating patient by a gynaecological oncology centre for potential cytoreduction options, given first relapse &gt;6 months after last platinum administration [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].&quot;,
  &quot;oncologist&quot;: &quot;Here&#x27;s my initial opinion:\n\nâ€¢ Patient has recurrent ovarian clear cell carcinoma with metastatic disease, last treated with 6 cycles of chemotherapy, relapsed biochemically [@20221229|9703212 | LAB].\nâ€¢ CA125 is elevated at 933.00 U/ml, indicating disease progression; further imaging and assessment required for treatment planning [@20221229|9703212 | LAB].\nâ€¢ Comprehensive NGS panel shows pathogenic mutation in ATM gene (Y316C), while BRCA1/2 and other genes tested negative [@OH2203828 | Genomics]; PARP inhibitor therapy may be considered, taking into account histotype and prior treatment outcomes [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10].&quot;,
  &quot;radiologist&quot;: &quot;Here are the imaging findings:\n\nâ€¢ Presacral mass increased in size with heterogeneous enhancement, suggesting progression of disease [@2022-12-29 | MR].\nâ€¢ Multiple hepatic metastatic nodules increased in number and size, indicating worsening disease trend [@2022-12-29 | CT].\nâ€¢ Pelvic mesenteric nodules likely metastases, with possible peritoneal metastases, as per imaging impression on 2022-12-30.&quot;,
  &quot;pathologist&quot;: &quot;Here are three bullets summarizing my initial opinion:\n\n* High-grade adenocarcinoma with ovarian clear cell carcinoma involvement suspected; full-thickness intestinal wall invasion observed.\n* Molecular testing results show a pathogenic ATM mutation (Y316C) [@OH2203828 | Genomics], but BRCA1/2 and other key genes are negative.\n* Tumor histology and molecular results should be reviewed in the context of NCCN Guidelines for ovarian cancer treatment [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18]; further assessment and discussion are needed to determine the best course of action.&quot;,
  &quot;nuclear&quot;: &quot;Here are my initial metabolic findings:\n\nâ€¢ Probable metastases in liver with multiple low-density nodules, largest 17mm*14mm, increased in size and number [@2022-12-29|CT].\nâ€¢ Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible [@2022-12-29|MR].\nâ€¢ PET findings are not available; needs update with latest PET-CT report to accurately assess metabolic activity.&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;FINAL ASSESSMENT / CORE TREATMENT STRATEGY / CHANGE TRIGGERS\n\n**Final Assessment:** Recurrent ovarian clear cell carcinoma with metastatic disease requires urgent assessment and treatment planning.\n\n**Core Treatment Strategy:**\n* Evaluate patient by a gynaecological oncology centre for potential cytoreduction options, given first relapse &gt;6 months after last platinum administration [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].\n* Utilize comprehensive NGS panel results, including ATM NM_000051:exon8:c.A947G:p.Y316C mutation, to inform treatment decisions [@OH2203828 | Genomics].\n* Consider further assessment with PET-CT to accurately assess metabolic activity, once updated report is available; current PET findings are unknown.\n\n**Change Triggers:**\nMonitor CA125 levels and imaging studies to assess response to treatment and adjust strategy as needed; current CA125 level is 933.00 U/ml [@20221229|9703212 | LAB].&quot;,
    &quot;oncologist&quot;: &quot;Here&#x27;s the FINAL refined plan:\n\nâ€¢ Evaluate patient by a gynaecological oncology centre for potential cytoreduction options, given first relapse &gt;6 months after last platinum administration [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].\nâ€¢ Urgently require further assessment and treatment planning due to elevated CA125 and imaging evidence of metastatic disease [@20221229|9703212 | LAB].\nâ€¢ Obtain missing critical information: BRCA/HRD testing status, HER2, MSI, PDL1, TMB results, and latest PET-CT report to accurately assess metabolic activity and inform comprehensive treatment decisions [@OH2203828 | Genomics].&quot;,
    &quot;radiologist&quot;: &quot;Given the lack of PET findings and missing critical molecular information, I will focus on providing refined imaging findings:\n\nâ€¢ Presacral mass increased in size with heterogeneous enhancement, suggesting progression of disease [@2022-12-29 | MR].\nâ€¢ Multiple hepatic metastatic nodules increased in number and size, indicating worsening disease trend [@2022-12-29 | CT].\nâ€¢ Further imaging assessments, including updated PET-CT, are necessary to accurately assess metabolic activity and inform treatment decisions.&quot;,
    &quot;pathologist&quot;: &quot;Here are the three bullets for the FINAL refined plan:\n\n* Urgent further assessment and treatment planning are required, given elevated CA125 and metastatic disease evidence [@20221229|9703212 | LAB].\n* Comprehensive NGS panel results [@OH2203828 | Genomics] and potential cytoreduction options should be considered, following evaluation by a gynaecological oncology centre [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].\n* Critical missing information, including tumor BRCA/HRD testing status, HER2, MSI, PDL1, and TMB results, must be updated to inform treatment decisions.&quot;,
    &quot;nuclear&quot;: &quot;Here is the refined metabolic plan:\n\nâ€¢ Obtain latest PET-CT report to accurately assess metabolic activity; currently missing.\nâ€¢ Consider evaluating patient by a gynaecological oncology centre for potential cytoreduction options [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].\nâ€¢ Comprehensive NGS panel results should inform treatment decisions, including BRCA/HRD testing status [@OH2203828 | Genomics].&quot;
  }
}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-03</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>nuclear</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr><tr><td class='mono'>oncologist</td><td>3</td><td>2023-01-03</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>pathologist</td><td>0</td><td>-</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>radiologist</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç¥ç»å…ƒç‰¹å¼‚çƒ¯é†‡åŒ–é…¶ 9.06 ng/ml (NSE)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 85.98 %(ç»ç»å) (ROMA.)\nç³–é“¾æŠ—åŸ15-3 86.00 U/ml (CA15-3)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 41.02 %(ç»ç»å‰) (ROMA)\näººé™„ç¾è›‹ç™½4 111.00 pmol/L (HE4)\nç™ŒèƒšæŠ—åŸ 1.49 ng/ml (CEA)\nç³–é“¾æŠ—åŸ125 933.00 U/ml (CA125)\nç³–é“¾æŠ—åŸ19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|10100203&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;æ€»èƒ†çº¢ç´  8.1 umol/l (TBIL)\nè°·æ°¨é…¸è„±æ°¢é…¶ 3.2 U/L (GLDH)\nÎ³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 34 U/L (GGT)\nå°¿ç´  4.24 mmol/l (UREA)\nç™½è›‹ç™½ 39.1 g/l (ALB)\næ€»è›‹ç™½ 70.4 g/l (TP)\nè°·è‰åŒå·¥é…¶ 7.3 U/L (ASTM)\nçƒè›‹ç™½ 31.3 g/l (GELO)\nå¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 26.5 U/L (AST)\nå°¿é…¸ 190 umol/l (UA)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.17 mmol/L (NEFA)\nç¢±æ€§ç£·é…¸é…¶ 109.4 U/L (ALP)\nå‰ç™½è›‹ç™½ 106 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  4.0 umol/L (IBIL)\nç›´æ¥èƒ†çº¢ç´  4.1 umol/l (DBIL)\nä¹³é…¸è„±æ°¢é…¶ 258 U/L (LDH)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 23.1 U/l (ALT)\nè‚Œé… 54 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.25 nan (A/G)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 76.5 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 12 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.01 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 0.20 % (BASO)\næ·‹å·´ç»†èƒæ•° 0.5 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 4.8 *10^9/L (GRAN#)\nçº¢ç»†èƒè®¡æ•° 2.84 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 259 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 18.6 % (RDWCV)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 305.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.28 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 57 nan (RDWSD)\nå•æ ¸ç»†èƒæ•° 0.9 *10^9/L (MID#)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— UNACCEPT nan (VFLAG)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 85.6 fl (MCV)\nç™½ç»†èƒè®¡æ•° 6.2 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 74 g/l (HGB)\nå—œé…¸æ€§ç»†èƒæ•° 0.00 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.00 % (EOS)\næ·‹å·´ç»†èƒ% 8.5 % (LYM)\nå•æ ¸ç»†èƒ% 14.8 % (MID)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 26.1 pg (MCH)\nçº¢ç»†èƒæ¯”ç§¯ 24.3 % (HCT)\nå¹³å‡PLTå®¹ç§¯ 10.9 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 9.60 nan (NL)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç¥ç»å…ƒç‰¹å¼‚çƒ¯é†‡åŒ–é…¶ 9.06 ng/ml (NSE)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 85.98 %(ç»ç»å) (ROMA.)\nç³–é“¾æŠ—åŸ15-3 86.00 U/ml (CA15-3)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 41.02 %(ç»ç»å‰) (ROMA)\näººé™„ç¾è›‹ç™½4 111.00 pmol/L (HE4)\nç™ŒèƒšæŠ—åŸ 1.49 ng/ml (CEA)\nç³–é“¾æŠ—åŸ125 933.00 U/ml (CA125)\nç³–é“¾æŠ—åŸ19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|10100203&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;æ€»èƒ†çº¢ç´  8.1 umol/l (TBIL)\nè°·æ°¨é…¸è„±æ°¢é…¶ 3.2 U/L (GLDH)\nÎ³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 34 U/L (GGT)\nå°¿ç´  4.24 mmol/l (UREA)\nç™½è›‹ç™½ 39.1 g/l (ALB)\næ€»è›‹ç™½ 70.4 g/l (TP)\nè°·è‰åŒå·¥é…¶ 7.3 U/L (ASTM)\nçƒè›‹ç™½ 31.3 g/l (GELO)\nå¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 26.5 U/L (AST)\nå°¿é…¸ 190 umol/l (UA)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.17 mmol/L (NEFA)\nç¢±æ€§ç£·é…¸é…¶ 109.4 U/L (ALP)\nå‰ç™½è›‹ç™½ 106 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  4.0 umol/L (IBIL)\nç›´æ¥èƒ†çº¢ç´  4.1 umol/l (DBIL)\nä¹³é…¸è„±æ°¢é…¶ 258 U/L (LDH)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 23.1 U/l (ALT)\nè‚Œé… 54 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.25 nan (A/G)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 76.5 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 12 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.01 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 0.20 % (BASO)\næ·‹å·´ç»†èƒæ•° 0.5 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 4.8 *10^9/L (GRAN#)\nçº¢ç»†èƒè®¡æ•° 2.84 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 259 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 18.6 % (RDWCV)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 305.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.28 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 57 nan (RDWSD)\nå•æ ¸ç»†èƒæ•° 0.9 *10^9/L (MID#)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— UNACCEPT nan (VFLAG)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 85.6 fl (MCV)\nç™½ç»†èƒè®¡æ•° 6.2 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 74 g/l (HGB)\nå—œé…¸æ€§ç»†èƒæ•° 0.00 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.00 % (EOS)\næ·‹å·´ç»†èƒ% 8.5 % (LYM)\nå•æ ¸ç»†èƒ% 14.8 % (MID)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 26.1 pg (MCH)\nçº¢ç»†èƒæ¯”ç§¯ 24.3 % (HCT)\nå¹³å‡PLTå®¹ç§¯ 10.9 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 9.60 nan (NL)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|CT&quot;,
        &quot;date&quot;: &quot;2022-10-24T16:02:31&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-4-6ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾¹ç•Œä¸æ¸…ï¼Œå¤§è€…çº¦16mm*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ï¼Œå·¦è¾“å°¿ç®¡å†…è§æ”¯æ¶ç®¡å½±ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘ç»“èŠ‚ï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ï¼Œè½¬ç§»å¯èƒ½ï¼Œè¯·ç»“åˆMRæ£€æŸ¥ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|CT&quot;,
        &quot;date&quot;: &quot;2022-10-24T16:02:31&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-4-6ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾¹ç•Œä¸æ¸…ï¼Œå¤§è€…çº¦16mm*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ï¼Œå·¦è¾“å°¿ç®¡å†…è§æ”¯æ¶ç®¡å½±ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘ç»“èŠ‚ï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ï¼Œè½¬ç§»å¯èƒ½ï¼Œè¯·ç»“åˆMRæ£€æŸ¥ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|CT&quot;,
        &quot;date&quot;: &quot;2022-10-24T16:02:31&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-4-6ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾¹ç•Œä¸æ¸…ï¼Œå¤§è€…çº¦16mm*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ï¼Œå·¦è¾“å°¿ç®¡å†…è§æ”¯æ¶ç®¡å½±ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘ç»“èŠ‚ï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ï¼Œè½¬ç§»å¯èƒ½ï¼Œè¯·ç»“åˆMRæ£€æŸ¥ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šç›†è…”æœ¯åï¼Œé˜´é“æ®‹ç«¯ç•¥åšï¼Œéª¶å‰è§ä¸è§„åˆ™è‚¿å—å½±ï¼Œè¾ƒå‰å¢å¤§ï¼Œç›®å‰èŒƒå›´çº¦53Ã—44mmï¼Œä¿¡å·è¾ƒå‰ä¸å‡ï¼Œç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯ï¼Œå³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚è†€èƒ±å……ç›ˆå¯ï¼Œå£æœªè§æ˜æ˜¾å¢åšã€‚ ç›†è…”æœ¯åï¼Œéª¶å‰å ä½èŒƒå›´è¾ƒå‰å¢å¤§ã€è¾ƒå‰å¼ºåŒ–ä¸å‡ï¼Œè€ƒè™‘å¤å‘ä¼´ç›¸é‚»è…¹è†œã€éª¶éª¨å—ç´¯å¯èƒ½ï¼Œè¯·ç»“åˆä¸´åºŠã€‚ å³ä¾§é«‚éª¨æ–°è§å¼ºåŒ–ç»“èŠ‚ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›†è…”ç³»è†œå¤šå‘å¼ºåŒ–å°ç»“èŠ‚åŒå‰ç›¸ä»¿ï¼Œè½¬ç§»å¯èƒ½ã€‚ ç›´è‚ å±€éƒ¨è‚ å£å¢åšä¼´å¼ºåŒ–ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2022-10-21ï¼šè‚å†…å¤šå‘ä½å¯†åº¦ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ï¼Œå¤§è€…çº¦17m*14mmï¼Œéƒ¨åˆ†è¾ƒå‰æ–°è§ã€‚è‚å†…å¦è§å¤šå‘å›Šæ€§æ— å¼ºåŒ–ç»“èŠ‚åŒå‰ã€‚è‚å†…è¡€ç®¡èµ°è¡Œæ­£å¸¸ï¼Œè‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾è„ç‰‡çŠ¶ä½å¯†åº¦å½±ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚ è‚å†…å¤šå‘è½¬ç§»ç»“èŠ‚ï¼Œè¾ƒå‰å¢å¤šï¼Œéƒ¨åˆ†è¾ƒå‰å¢å¤§ã€‚ å¦è§è‚å›Šè‚¿åŒå‰ã€‚ è„¾è„ç‰‡çŠ¶å½±ï¼Œè„¾è„æ¢—å¡ï¼Ÿéšè®¿ã€‚&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;nuclear&quot;: []
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Guideline + PubMed RAG</summary>
    <h3>RAG Query</h3>
    <pre>Patient with ovarian clear cell carcinoma, platinum status unknown, metastases to liver, pelvis, and sacrum, HRD-negative, BRCA-negative, ATM mutation (Y316C), and normal organ function, seeking further treatment options; histology: clear cell carcinoma</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre># GUIDELINE RAG
RAG Evidence Pack (top=5):
[1] score=0.6640 nccn_ovariancancer_v3_2025__v00000000 [PAGE 18] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18]
    Version 3.2025, 07/16/25 Â© 2025 National Comprehensive Cancer NetworkÂ® (NCCNÂ®), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN. Note: All recommendations are category 2A unless otherwise indicated. NCCN Guiâ€¦
[2] score=0.6416 nccn_ovariancancer_v3_2025__v00000000 [PAGE 14] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 14]
    ff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of disease; clinical judgment and flexibility should be utilized in determining treatment options. gg Data are limited on primary and maintenance therapy for recurrent/ persistent LCOC. hh During and after treatâ€¦
[3] score=0.6398 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 11] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]
    cytoreduction o Residual ChT toxicity o The patientâ€™s general condition and preferences  Patients with ï¬rst relapse of ovarian cancer after &gt;6 months of last platinum administration should be evalu- ated by a gynaecological oncology centre experienced in surgery for ovarian cancer to identify potenâ€¦
[4] score=0.6390 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 10] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10]
    with ï¬rst line. This can probably be explained by an accu- mulative exposure to platinum.85 Several factors need to be taken into consideration for the selection of PARPis or anti-VEGF therapies in relapse including histotype, BRCA1/2-mut status, prior therapies (PARPi and/or bevacizumab), expected â€¦
[5] score=0.6261 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]
    n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D). dd Validated molecular testing should be performed in a CLIA-approved facility using the most recent available tumor tissue. Tumor molecular analysis is recommended to include, at a minimum, tests to identify potentâ€¦

# PUBMED RAG
(PUBMED: retrieval failed: 500 Server Error: Internal Server Error for url: http://495ga8uy7084.vicp.fun:17088/api/search-paper)</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.663996696472168,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 18,
    &quot;text&quot;: &quot;Version 3.2025, 07/16/25 Â© 2025 National Comprehensive Cancer NetworkÂ® (NCCNÂ®), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nClear Cell Carcinoma of the Ovary\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nClear cell carcinoma\nof the ovaryg,h,i\nStage\nIC2â€“ IC3\nStage IA\nIB, IC1\nStage IIâ€“IV\nIV platinum-based therapy\n(see primary regimens for stage I disease\n[OV-C, 5 of 12])\nIV platinum-based therapy\n(see primary regimens for stage I disease\n[OV-C, 5 of 12])\nor\nObserveg\nSystemic therapy\n(OV-C, 6 of 12)\nLCOC-3\nPATHOLOGIC\nDIAGNOSISa\nADJUVANT TREATMENTf\nMONITORING/\nFOLLOW-UP\nMonitoring/Follow-up\n(including tumor testing)\nand\nRecurrence therapyj\n(OV-6)\nIf known BRCA1/2\nmutation, consider\nmaintenance therapy\n(post-primary therapy)\n(OV-5)\na WHO Histologic Classification (OV-E).\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ng If not previously done, consider surgical staging and resection of residual disease (OV-3).&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.641573429107666,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 14,
    &quot;text&quot;: &quot;ff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.\ngg Data are limited on primary and maintenance therapy for recurrent/\npersistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated\nas indicated with tumor markers and repeat imaging (with modalities\npreviously used) to document response and/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\njj Patients who do not respond and progress on two consecutive regimens\nwithout evidence of clinical benefits have diminished likelihood of\nbenefitting from additional therapy (Griffiths RW, et al. Int J Gynecol\nCancer 2011;21:58-65). Decisions to offer clinical trials, supportive care,\nor additional therapy should be made on an individual basis.\nkk Localized radiation therapy (RT) can be considered to palliate\nsymptoms and/or for oligometastatic disease.\nOV-8\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6398172378540039,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 11,
    &quot;text&quot;: &quot;cytoreduction\no Residual ChT toxicity\no The patientâ€™s general condition and preferences\n\u0004 Patients with ï¬rst relapse of ovarian cancer after &gt;6\nmonths of last platinum administration should be evalu-\nated by a gynaecological oncology centre experienced in\nsurgery for ovarian cancer to identify potential candi-\ndates for surgical cytoreduction [I, A].\n\u0004 Patients who have previously responded to platinum\nwithout early symptomatic relapse should be treated\nwith either a platinum-based doublet (PLD, gemcitabine\nor paclitaxel) with bevacizumab [I, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3]\nor a platinum-based doublet followed by maintenance\nwith PARPi therapy if a response is achieved and the\npatient has not been previously exposed to PARPis\n[I, A; olaparib for BRCA1/2-mutated: ESMO-MCBS v1.1\nscore: 2; niraparib regardless of BRCA1/2-mut status:\nESMO-MCBS v1.1 score: 3; rucaparib regardless of\nBRCA1/2-mut status: ESMO-MCBS v1.1 score: 3].\n\u0004 For patients requiring rapid response, the combination\nof a platinum-based doublet (PLD, gemcitabine or pacli-\ntaxel) with bevacizumab is preferred [V, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3].&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6390154361724854,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;with ï¬rst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciï¬cally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6261396408081055,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using the\nmost recent available tumor tissue. Tumor molecular analysis is recommended to include,\nat a minimum, tests to identify potential benefit from targeted therapeutics that have tumor-\nspecific or tumor-agnostic benefit including, but not limited to, HER2 status (by IHC),\nBRCA1/2, HRD status, MSI, MMR, TMB, BRAF, FRÎ± (FOLR1), RET, and NTRK if prior\ntesting did not include these markers. More comprehensive testing may be particularly\nimportant in LCOC with limited approved therapeutic options (OV-B).\nee Tumor molecular testing prior to initiation of therapy for persistent/recurrent disease, if not\npreviously done.\nff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of\ndisease; clinical judgment and flexibility should be utilized in determining treatment options.\nCombination platinum-\nbased chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive&quot;
  }
]</pre>
    <h3>Evidence Digest (1:1 per RAG result)</h3>
    <pre>Here are the exactly 5 evidence bullets, one per RAG result, in order:

â€¢ For ovarian cancer treatment, all recommendations are category 2A unless otherwise indicated, as per NCCN Guidelines [1] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18].

â€¢ Clinical judgment and flexibility should be utilized in determining treatment options for platinum-sensitive and platinum-resistant disease, as the definitions represent a spectrum of disease [2] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 14].

â€¢ Patients with first relapse of ovarian cancer after &gt;6 months of last platinum administration should be evaluated by a gynaecological oncology centre experienced in surgery for ovarian cancer to identify potential cytoreduction options [3] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].

â€¢ Selection of PARPis or anti-VEGF therapies in relapse should consider histotype, BRCA1/2-mut status, prior therapies, and expected treatment outcomes [4] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 10].

â€¢ Validated molecular testing should be performed in a CLIA-approved facility using the most recent available tumor tissue, and should include tests to identify potential genetic mutations [5] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].</pre>
  </details>

  <details class='mt mermaid-container' open><summary>Pipeline Flow</summary><div class='mermaid-chart'>flowchart TD
  A[Load Case + Fingerprint] --> B[Load Reports]
  B --> C[Report Selection per Role]
  C --> D[Guideline+PubMed RAG]
  D --> E[Init Specialist Agents]
  E --> F[MDT Discussion Engine]
  F --> G[Trial Matching]
  G --> H[Final Chair Output]
  H --> I[Save Logs]</div></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-21T08:26:54.600051&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-01-03 08:53:29.260000&quot;,
      &quot;meta_info&quot;: &quot;340123197709263626&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:26:54.600568&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;2a31f255c155&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:26:54.863395&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 92,
      &quot;img_n&quot;: 10,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2023-01-04 08:53:29&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:01.068075&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|10100203|2023-01-03&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|10100203|2023-01-03&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2022-10-24|CT|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2022-10-24|CT|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2022-10-24|CT|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:01.071282&quot;,
    &quot;event&quot;: &quot;rag_key_facts&quot;,
    &quot;payload&quot;: {
      &quot;facts&quot;: &quot;DIAGNOSIS: primary=åµå·¢ç™Œå¤å‘; histology=é€æ˜ç»†èƒç™Œ; è‚ å£å…¨å±‚è§é«˜çº§åˆ«è…ºç™Œ; components=High-grade adenocarcinoma involving full-thickness intestinal wall;Lymph node metastasis (4/15);Peritoneal/rectal/vaginal involvement described\nPATHOLOGY: Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\nPLATINUM: status=Resistant; pfi_days=56\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=&lt;0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; full_text=ATM NM_000051:exon8:c.A947G:p.Y316Cï¼ˆèƒšç³»ï¼‰ï¼›HRD é˜´æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:17.068793&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Patient with ovarian clear cell carcinoma, platinum status unknown, metastases to liver, pelvis, and sacrum, HRD-negative, BRCA-negative, ATM mutation (Y316C), and normal organ function, seeking further treatment options; histology: clear cell carcinoma&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:17.068805&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;guideline&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:17.068807&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;pubmed&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 0
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:17.068809&quot;,
    &quot;event&quot;: &quot;rag_hits_merged&quot;,
    &quot;payload&quot;: {
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:29.049924&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:29.050015&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;order&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:37.783600&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;chars&quot;: 561
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:37.783668&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;order&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:44.867766&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;chars&quot;: 669
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:44.867848&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;order&quot;: 3
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:49.546006&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;chars&quot;: 400
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:27:49.546073&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;order&quot;: 4
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:28:00.930570&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;chars&quot;: 597
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:28:00.930634&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;order&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:28:07.416678&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;chars&quot;: 419
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:29:13.515767&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 0
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:29:13.517698&quot;,
    &quot;event&quot;: &quot;trial_matching_start&quot;,
    &quot;payload&quot;: {
      &quot;trials_json_path&quot;: &quot;files/all_trials_filtered.json&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:29:13.994537&quot;,
    &quot;event&quot;: &quot;trial_matching_end&quot;,
    &quot;payload&quot;: {
      &quot;recommended&quot;: true
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:29:13.994555&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-21T08:29:31.172932&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 1787
    }
  }
]</pre>
  </details>

  <!-- Mermaid.js for flowchart rendering -->
  <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      mermaid.initialize({
        startOnLoad: true,
        theme: 'default',
        flowchart: {
          useMaxWidth: true,
          htmlLabels: true,
          curve: 'basis'
        },
        securityLevel: 'loose'
      });
      // Re-render mermaid charts in .mermaid-chart containers
      document.querySelectorAll('.mermaid-chart').forEach(function(el) {
        el.classList.add('mermaid');
      });
      mermaid.init(undefined, '.mermaid-chart');
    });
  </script>
</body>
</html>
